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Background: There is currently no gold standard for assessing antiretroviral (ARV) adherence, 
so researchers often resort to the most feasible and cost-effective methods possible (eg, self-
report), which may be biased or inaccurate. The goal of our study was to evaluate the feasibility 
and acceptability of innovative and remote methods to estimate ARV adherence, which can 
potentially be conducted with less time and financial resources in a wide range of clinic and 
research settings. Here, we describe the research protocol for studying these novel methods 
and some lessons learned.
Methods: The 6-month pilot study aimed to examine the feasibility and acceptability of a 
remotely conducted study to evaluate the correlation between: 1) text-messaged photographs 
of pharmacy refill dates for refill-based adherence; 2) text-messaged photographs of pills for 
pill count-based adherence; and 3) home-collected hair sample measures of ARV concentration 
for pharmacologic-based adherence. Participants were sent monthly automated text messages to 
collect refill dates and pill counts that were taken and sent via mobile telephone photographs, 
and hair collection kits every 2 months by mail. At the study end, feasibility was calculated by 
specific metrics, such as the receipt of hair samples and responses to text messages. Participants 
completed a quantitative survey and qualitative exit interviews to examine the acceptability of 
these adherence evaluation methods. The relationship between the 3 novel metrics of adherence 
and self-reported adherence will be assessed.
Discussion: Investigators conducting adherence research are often limited to using either 
self-reported adherence, which is subjective, biased, and often overestimated, or other more 
complex methods. Here, we describe the protocol for evaluating the feasibility and acceptability 
of 3 novel and remote methods of estimating adherence, with the aim of evaluating the relation-
ships between them. Additionally, we note the lessons learned from the protocol implementation 
to date. We expect that these novel measures will be feasible and acceptable. The implications 
of this research will be the identification and evaluation of innovative and accurate metrics of 
ARV adherence for future implementation.
Keywords: adherence assessment, HIV, hair measures, pill counts, pharmacy refills, remote 
study, text message, antiretroviral therapy, PrEP
Background
Strict adherence to antiretroviral (ARV) medications is critical for attaining human 
immunodeficiency virus (HIV) treatment goals, such as sustained suppression of plasma 
HIV RNA, decreased risk of developing drug resistance, improved quality of life, 
and reduced risk of HIV transmission.1–3 Commonly used methods to estimate ARV 
adherence include patient’s self-report, pharmacy refill data, pill counts, medication 
event monitoring system (MEMS) caps, and analysis of drug levels in a biomatrix (eg, 
plasma, dried blood spots, and hair). However, there is no gold standard of assessing 
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adherence,1 and clinicians and researchers often resort to the 
most feasible and cost-effective methods possible, which may 
result in biased or inaccurate estimates.
Investigators conducting adherence research are often 
limited to using either self-reported adherence, a subjec-
tive and potentially overestimated measure that is prone to 
recall and social desirability biases,4,5 or other more complex 
methods, such as pharmacologic measures or electronic drug 
monitoring, which require expertise and financial resources. 
Numerous direct measurement methods (eg, quantification of 
concentrations of active drug or metabolites in the blood,6–8 
urine,9 and hair10,11) and indirect methods (eg, patient self-
report,12–14 pharmacy refill records,15,16 pill counts,12 and use 
of MEMS caps12,14) have been employed, but there is no con-
sensus over the best approach to assess medication adherence. 
Each method has advantages and disadvantages.
Additionally, most ARV adherence research to date has 
required the physical presence of participants at a study site 
to take part in studies. This may create difficulties in recruit-
ment and retention given the burden associated with the need 
to have access to modes of and funds for transportation and 
the time required for visits. These time and resource costs 
are further exacerbated when the study requires multiple 
visits. Furthermore, among people living with HIV (PLWH), 
perceived stigma or negative social consequences associated 
with participating in research may be the important barriers 
to participation.17 In addition to personal inconveniences, 
these barriers to research participation can result in missing 
data and potentially biased results.
In this study, we evaluated the feasibility and accept-
ability of 3 innovative methods to estimate ARV adher-
ence using remote collection of data. These novel methods 
involve text-messaged photographs of pharmacy refill dates, 
text-messaged photographs of pills for pill count, and home 
collection of hair samples. All 3 can be conducted relatively 
quickly and with limited financial resources in a wide range of 
health care systems and research settings. Here, we describe 
our research protocol and lessons learned.
Methods
Study overview and design
We conducted a 6-month study to 1) assess the feasibil-
ity and acceptability of novel methods of estimating ARV 
adherence using text-messaged photographs of pharmacy 
refill dates and pill counts and home-collected hair samples; 
2) examine the feasibility and acceptability of a study 
where all study activities, including recruitment, consent, 
hair sample collection, text messaging, and exit interviews, 
were conducted remotely; and 3) explore the relationship 
between ARV adherence based on self-report and the 3 novel 
metrics, specifically text-messaged photographs of pharmacy 
refill dates and pill counts, and drug levels in hair samples 
collected at home.
Table 1 provides an overview of the study. Participants 
were asked to mail back home-collected hair samples at 
baseline, 2, 4, and 6 months using the hair collection kits 
sent to them by study staff. At baseline and once monthly, for 
6 months, participants were sent 4 text messages, referred to 
as Adherence Survey, asking them to 1) rate their ARV medi-
cation adherence using a validated self-report item,18 2) text 
message a photograph of the refill date on the ARV medica-
tion bottle that they were using at that time, 3) text message a 
photograph of the contents inside the ARV medication bottle 
or pillbox that they were using at that time, and 4) the approxi-
mate date when they picked up their latest ARV refill from 
the pharmacy. Additionally, at baseline and at 6 months, par-
ticipants were asked about any extra ARV pills that they may 
have (ie, stock supply of medications). Finally, at 6 months, 
we conducted quantitative feasibility and acceptability surveys 
and qualitative exit interviews. We received approval from the 
University of California, San Francisco (UCSF) Institutional 
Review Board to conduct this study, and written informed 
consent was obtained from all participants.
Inclusion and exclusion criteria
Adults living with HIV who met the following criteria were 
eligible for study participation:
1. Being on 1 ARV regimen for at least 3 consecutive months 
prior to participation and report that they were unlikely to 
change ARV medications in the next 6 months: to allow 
Table 1 Study overview
Study activities Months
0 1 2 3 4 5 6
Enrollment visit
telephone screener X
Email consent X
Email link to survey X
Inventory of stock medications X
text message
Adherence self-report X X X X X X X
Refill date photo X X X X X X X
Pill count photo X X X X X X X
Medication pickup date X X X X X X X
Hair collection
Mail collected hair to study X X X X
Final study visit
Inventory of stock medications X
Quantitative exit survey X
Qualitative exit interview X
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enough time for individuals to become familiar with 
their new regimen, make any changes in case of adverse 
effects, accumulate sufficient ARV levels in their hair, 
and allow study staff to monitor 1 ARV regimen during 
the 6 months of the study.
2. Being on ARV regimens containing tenofovir (TFV) 
(either tenofovir disoproxil fumarate [TDF] or tenofovir 
alafenamide [TAF]), emtricitabine (FTC), darunavir 
(DRV), or dolutegravir (DTG): these ARV medications 
currently have validated assays in hair in the UCSF Hair 
Analytical Laboratory (HAL) and were part of the first-
line regimens recommended at the Department of Health 
and Human Services guidelines at the time of this study.19 
The brand names of ARV regimens that included these 
medications were Atripla, Complera, Descovy, Emtriva, 
Genvoya, Odefsey, Prezcobix, Prezista, Stribild, Tivicay, 
Triumeq, Truvada, and Viread.
3. Have access to a mobile telephone that supported 
photography and transmission of the photographs via 
text message (note that this included any basic mobile 
telephone with a camera and a data plan): this allowed 
participants to take photographs of the refill dates and 
pill counts to send to study staff.
4. Have access to the Internet (through mobile tele-
phones, personal computers, or public computers): this 
allowed for study staff to email consent forms, base-
line surveys, exit quantitative survey, as well as other 
communications.
Participants who reported receiving automated refills (and 
thus not having any active role in receiving their next refill 
through either contacting their pharmacy to generate a new 
refill or physically picking up their refill from the pharmacy), 
those who had chronic kidney disease necessitating 
renallydosed ARVs, and those who were unable to provide 
hair samples (due to baldness or other reasons, such as 
wearing a weave that prevented individuals from cutting hair 
close to the scalp) were excluded from the study.
recruitment
We advertised on online social media (ie, Facebook and Ins-
tagram) to recruit participants nationwide. Participants were 
offered a total of $270 for all study activities (see Section 
“Incentive Structure”). We spent a total of US$1,300 over 
4 weeks for advertisement. The mean cost per click was 
~$0.36, and we had about 2,771 clicks. We narrowed our 
advertisements to be shown to adults (.18 years of age) 
living in the USA and used key terms related to HIV; acquired 
immunodeficiency syndrome (AIDS); lesbian, gay, bisexual, 
and transgender; homosexuality; ACT UP; and same-sex 
marriage.
In addition to the online social media advertisements, we 
created a Facebook page (www.facebook.com/RxPixStudy), 
a Twitter account (twitter.com/rxpixstudy), and a website 
(rxpix.ucsf.edu/) to further improve our web presence and 
provide additional information about the study. We sent a 
total of 25 emails to organizations serving PLWH nationwide 
to notify them about our study, posted flyers at clinics serving 
PLWH in the San Francisco Bay Area, and asked the UCSF 
Center for AIDS Prevention Studies Community Advisory 
Board to assist us in recruitment through email, social media, 
and word of mouth. Finally, through snowball sampling, we 
offered our participants $10 for each eligible individual they 
referred who consented to participate in the study.
Enrollment
Participants who emailed, called, or text messaged the study 
staff were given a brief description of the study, including 
the study’s interest in collecting hair samples, to assess the 
participant’s ability and willingness to submit hair samples. 
Interested individuals were then screened according to 
the inclusion/exclusion criteria. Those who were eligible and 
interested were asked for their contact information (including 
mobile telephone number; other telephone numbers; mailing 
address; email address; friend or family contact information; 
and social media [Facebook, Instagram, Twitter, Snapchat, 
and others] usernames). At this time, participants were sched-
uled for a 30-minute enrollment call before which they were 
requested to view “The RxPix Study: What to Expect” video 
(http://rxpix.ucsf.edu/videos) and gather all of their ARV 
medication containers in one place for an inventory. During 
the enrollment call, participants were given an opportunity 
to ask questions about the study activities, including the hair 
collection video. If they remained interested, they were then 
emailed a link to the consent form and baseline survey.
data collection
Qualtrics (Qualtrics, Provo, UT, USA; version March 2017), 
a data collection software to conduct online surveys, was used 
to obtain informed consent and collect initial demographic 
and clinical data, and for the final exit survey. The links to 
these surveys were emailed to participants. The baseline sur-
vey included questions regarding demographics (age, race/
ethnicity, sex/gender, sexual orientation, income, and educa-
tion), use of alcohol or other substances, HIV clinical outcomes 
(CD4+ cell count, detectability of HIV viral load) engagement 
in HIV care, names of ARV medications, medication adherence 
over the past 30 days based on the visual analog scale20 and 
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the rating scale,18 barriers to and facilitators of adherence,21,22 
and familiarity of use of technology for health care.
At baseline and for months 1 through 6, we collected 
adherence data using text messaging. For this, we used the 
services of a company named Mosio, which offers text mes-
saging software for clinical research, to automate the sending 
of our Adherence Surveys on a monthly basis and reminder 
text messages as needed. During the study, we used text 
messaging, telephone, and email to contact participants. The 
qualitative exit interviews were conducted by telephone and 
were audio-recorded.
Study outcomes
Study outcomes included the feasibility and acceptability of 
the various methods of estimating ARV medication adher-
ence (ie, text-messaged photographs of pharmacy refill dates 
and pill counts and home-collected hair samples), the feasibil-
ity and acceptability of a study where all study activities were 
conducted remotely, and the relationship between the various 
methods of ARV medication adherence estimation.
For feasibility and acceptability of our adherence- 
estimating methods and the remote research methodology, at 
6 months, we conducted a quantitative survey among all study 
participants and a qualitative exit interview with one-third of 
participants who met the criteria for the following categories: 
1) On Time: those who responded to the Adherence Survey 
and sent hair samples within the “early window period”, that 
is, within 5 days after the Adherence Survey was sent and 
11 days after hair kit was sent (N=12); 2) Early Inconsistent 
Hair Samples: participants who sent 1 or more hair samples up 
to 6 days after the “early window period” for hair sample, that 
is, 11 days after hair kit was sent (N=5); 3) Late Inconsistent 
Hair Samples: participants who sent 1 or more hair samples at 
least 7 days after the “early window period” for hair samples 
or not at all (N=5); 4) Inconsistent Texts: those who at any 
point in the study responded to the Adherence Surveys after 
the “early window period” for text message (ie, within 5 days 
after the Adherence Survey was sent) or did not complete 
the Adherence Survey at all (N=3); and 5) Least Consistent: 
participants who responded to the Adherence Surveys after 
the text message and sent their hair samples after the “early 
window period” or not at all (N=6).
During these interviews, participants were asked about 
1) the difficulties with each study component (text messaging, 
hair collection, etc.); 2) the likelihood of participating in other 
studies using a similar design; 3) the perceptions on privacy 
and security of data; 4) the perceptions on the potential 
impact of study procedures on their medication adherence, 
5) the advantages and disadvantages of participating in an 
entirely remotely conducted research project, and 6) the prob-
lems with the collection of hair samples or ease of following 
hair collection instructions. Exit interviews lasted about 30 
minutes and were audio-recorded for analysis.
In addition to the list of specific technological problems 
(eg, mobile telephone breaks in service, email-related issues, 
etc.), we examined the feasibility using prespecified feasibil-
ity measures, which were evaluated by specific metrics as 
listed in Table 2.
text messaging
The mobile telephone number of enrolled participants was 
entered into a Health Insurance Portability and Accountability 
Act-compliant clinical research text messaging software called 
Mosio. For individuals who were taking .1 ARV pill per day 
(eg, those not on fixed-dose combinations), we chose to study 
a particular target ARV based on a prespecified hierarchy 
Table 2 Feasibility measures and metrics
Feasibility measures Feasibility metrics
1. Mean number of days between the study’s first text  
message each month requesting text-messaged  
photographs and participants’ responses
At least 80% of responses within 5 days of our first text message request
2. Mean number of reminder text messages required  
to elicit a response from the participant
A mean of 2 additional reminder text messages per participant for the  
duration of the study
3. Mean frequency of nonresponse A mean of 2 nonresponses per participant for the study duration
4. Ability to extract the necessary information from  
images (mean number of attempts to receive clear  
pictures with the required information)
A mean of 2 additional text message attempts per participant for the  
duration of the study
5. Mean length of time to recruit study participants Mean duration of 3 months
6. Percentage of participants retained until the end of  
the study
text-messaged photographs of medication vials and vial contents at  
6 months from over 80% of participants
7. Mean number of mailed hair samples per participant receipt of 3 out of 4 mailed hair samples from at least 80% of participants
8. Number of participants with whom we successfully  
conduct exit surveys and qualitative exit interviews
conducting surveys with at least 80% of study participants and qualitative  
interviews with 30%
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(TDF . FTC . DRV . DTG . TAF). The hierarchy was 
based on the amount of research performed on specific ARV 
levels in hair. At this time, participants were sent 4 sequential 
text messages:
1. Thinking back over the past 30 days, please rate your 
ability to take all your medications as prescribed: 
1) Excellent, 2) Very good, 3) Good, 4) Fair, 5) Poor, 
and 6) Very poor.18
2. Thanks! Next, please text me a photo of the refill date on 
the bottle you are using now.
3. Thanks! Next, please text me a photo of the pills you 
have left in the bottle you are using now.
4. Great! Finally, please text me the date when you actually 
picked up your most recent refill (take your best guess).
These messages were responded to during the initial 
telephone enrollment meeting so that participants could ask 
questions, their mobile telephones could be tested for text 
messaging photographs, any technical issues around picture 
quality and text messaging could be resolved, and study staff 
could collect baseline data.
In addition to baseline, participants were asked these 
questions for months 1 through 6. Participants who did not 
respond were sent an automated reminder text message 1 and 
4 days after they received these text messages. To encour-
age participants to send us their text message responses in 
a timely manner, we created an “early window period” of 
5 days after receipt of the Adherence Survey as a metric of 
performance.
Hair sample
Medication concentrations in hair reflect drug uptake from 
the systemic circulation over weeks to months and provide 
a mean measure of ARV exposure.23,24 The UCSF HAL has 
pioneered the use of small hair samples to monitor ARV 
medication adherence,10,11,24–39 has developed methods to 
extract and analyze ARV levels from hair,31,32 and demon-
strated that hair ARV levels are the strongest independent 
predictor of virologic success.11,28,29,39 Unlike phlebotomy, 
hair collection is noninvasive and does not require specific 
skills, sterile equipment, or specialized storage conditions. In 
a prior study,40 we had demonstrated that the home collection 
of hair was feasible and acceptable, and that there was a high 
degree of correlation and agreement between ARV levels in 
hair collected by trained study staff and at home by partici-
pants, as well as between hair collected from the back and side 
of the head, all without the evidence of measurement bias.
The UCSF HAL performed the assays for ARV levels in 
hair. With its predecessor (the Drug Studies Unit) formed 
in 1977, this laboratory is equipped with modern facilities 
and highly trained staff to provide fully automated analysis 
for drugs and metabolites. The HAL has developed and 
reported methods to analyze TFV as well as other ARVs 
in human hair samples using liquid chromatography/tan-
dem mass spectrometry (LC/MS-MS).24,28,29,31,32,41–44 Most 
of the HAL assays have been peer reviewed and approved 
by the National Institutes of Health’s Division of AIDS 
Clinical Pharmacology and Quality Assurance Program.45 
Hair samples are collected using previously described 
methods, the proximal section (side closest to the scalp) is 
cut to 1.0 cm (representing the past month of exposure), 
the relevant ARV is extracted using optimized methods and 
analyzed via LC/MS-MS. For example, TFV in participants 
on either TDF or TAF is extracted with 50% methanol/
water containing 1% trifluroacetic acid, 0.5% hydrazine 
dihydrochloride, and internal standard in a 37°C shaking 
water bath overnight (.12 hours) and analyzed by LC/
MS-MS.41 The relative error (%) and precision (coefficients 
of variation) for spiked quality control hair samples at 
low, medium, and high concentrations are all ,15%. This 
method to analyze TFV levels in hair was validated from 
0.002 to 0.400 nanogram per milligram (ng/mg) hair, with 
a lower limit of quantitation at 0.002 ng/mg.42,46 In addition 
to TFV and FTC, HAL will analyze hair ARV levels for 
DRV and DTG.
We mailed participants hair collection kits containing 
2 alcohol wipes, 1 piece of aluminum foil (cut into 4 × 4 
inches), 2 adhesive labels, a sealable storage plastic bag 
(marked with the participant’s unique identification number), 
2 desiccant packs, and a self-posted envelope addressed to 
our university office. These kits included detailed instructions 
for hair collection (http://rxpix.ucsf.edu/hair-collection-
instructions) and the video link on our website demonstrating 
home collection of hair (http://rxpix.ucsf.edu/videos). Hair 
collection kits were mailed at baseline, 2, 4, and 6 months, 
and were sent 11 days before the sample due date. To encour-
age the participants to mail us their hair samples in a timely 
manner, we defined an “early window period” of 11 days after 
mailing of the hair collection kit as the goal. Hair samples 
can be stored at room temperature and are not biohazardous, 
so are easy to store and ship. The HAL was asked to provide 
hair ARV levels based on the prespecified ARV hierarchy 
(TDF . FTC . DRV . DTG . TAF). In other words, 
if a participant was taking multiple ARVs that could have 
been measured, the HAL used this hierarchy to determine 
the order of analysis while being attentive to the amount of 
hair sample available.
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Incentive structure
We offered a total of $270 for the timely completion of all 
study activities, which was provided to participant via Clin-
Card, a reloadable debit card that enabled remote participant 
reimbursements via a web-based portal. The incentive break-
down included $10 for baseline test text messages and $15 
for 4 text messages at months 1 through 6, $5 for timely text 
message response (ie, text message photographs sent within 
5 days of request) each month, $10 for the baseline survey, 
and $20 for the exit survey/interview. We used a gradually 
increasing incentive structure for the hair sample collection 
and shipment: $15 for the receipt of baseline hair sample, 
$20 for the 2-month hair sample, $25 for the 4-month hair 
sample, and $30 for the 6-month hair sample. Participants 
were offered an additional $5 for each hair sample mailed 
in a timely manner (ie, postmarked within 11 days after 
mail-out of hair kit).
We extracted the following information from the ARV 
medication vial photographs: medication name, total num-
ber of tablets dispensed at the time of refill, and refill date. 
From the photograph of the contents of their ARV medica-
tion vial, we counted the number of tablets remaining to 
establish adherence based on pill count.47,48 Additionally, 
at baseline and months 2, 4, and 6, we asked participants to 
mail us home-collected hair samples using our hair collection 
kits after viewing an online demonstration of the process. 
Finally, we conducted online exit surveys and telephone 
interviews with participants to evaluate the acceptability 
of our research methodology and their experience with the 
home collection of hair samples. Ability to comply with 
monthly text messaging and frequency of late or nonresponse 
constituted parameters for assessing the feasibility of this 
novel adherence-estimating method. Our ability to conduct a 
completely remote research project was used to evaluate the 
overall feasibility of our study design. Participants’ responses 
to exit surveys and interviews were used to assess accept-
ability via quantitative and qualitative methods.
Sample size estimates
Self-reported adherence and TFV levels in hair have a 0.34 
correlation at 8 weeks.26 Given that self-report is subjective 
and is frequently overestimated, 0.34 is the minimum correla-
tion that we required between our novel text message-based 
adherence measure and TFV levels in hair. To detect a 
minimum correlation of $0.34 at 6 months, we needed a 
minimum of 65 participants. We assumed a 20% attrition 
during the course of the study to calculate the total number 
of participants that we needed to enroll at baseline (N=82).
Planned data analysis
For our future data analysis, one-way frequency tables will 
be generated for all feasibility and acceptability measures. 
Audio-recorded interviews will be transcribed by a transcrip-
tionist. For analysis of these recordings, broad themes will 
be identified, refined through discussion, and entered into a 
matrix using Microsoft Excel where each column corresponds 
to a theme and each row represents a case. This method allows 
for the identification of patterns in the distribution of themes 
for data analysis.49 One investigator will categorize each 
interview (N=31) using this matrix. Another investigator will 
double code a random subsample (N=7) of the interviews, 
and coding discrepancies will be discussed by the 2 authors 
until consensus is reached or arbitrated by the first author. 
Collectively, the results from the quantitative exit survey 
analyses will complement the qualitative interview data.
Measures
Self-reported ARV medication adherence was evaluated by 
the adherence rating scale.18 This single item has been linked 
to more objective adherence estimates, that is, MEMS caps. 
The approximate correlation with adherence percentage 
based on MEMS caps is as follows: very poor=0%, 
poor=20%, fair=40%, good=60%, very good=80%, and 
excellent=100%.
We will calculate refill date-based measure of adherence 
(from text-messaged photos of ARV regimen vials) using the 
medication possession ratio (MPR) and proportion of days 
covered (PDC) formulas.50 MPR is the ratio of the sum of 
days’ supply for all fills in a specific period divided by the 
number of days in the period. PDC is the total number of 
days’ supply in a specific period “covered” divided by the 
number of days in the period. MPR may result in an overes-
timation of adherence because it does not take overlapping 
days into account; therefore, it will be capped at 100%. These 
formulas yield a value of 0%–100%.
We will calculate pill count-based ARV adherence using 
the methods established by Bangsberg and Kalichman.47,48,51 
It will be estimated by the difference between tablets counted 
by the study staff in 2 consecutive text-messaged photographs 
sent by the participant (eg, difference between the current and 
previous pill counts) divided by the total doses prescribed in 
a certain time period (eg, total number of tablets that should 
have been taken during the 30 days). This value will take 
into account the number of pills dispensed during that time 
period. This formula yields a value of 0%–100%.
Finally, ARV levels in hair at baseline, and months 
2, 4, and 6 will be measured as ng/mg hair and will be 
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log-transformed to reduce skewed levels. We will assess hair 
concentrations as continuous measures. Prior studies have 
shown a graded relationship between hair ARV levels and 
virologic outcomes.11,28,43
Statistical analysis
First, we will conduct univariate analyses (eg, one-way 
frequency tables, measures of central tendency, and variabil-
ity) to participants’ baseline and exit surveys and standings 
on the feasibility measures listed in Table 2. We will then 
describe the correlation of ARV levels in hair averaged across 
baseline, and months 2, 4, and 6 with adherence estimated 
based on the rating scale, refill dates, and pill counts aver-
aged over the 6-month study. Next, we will investigate the 
longitudinal relationship of ARV refill data, pill count, and 
ARV levels in hair at months 2, 4, and 6. These analyses will 
take advantage of the longitudinal nature of the data by using 
multilevel mixed-effects or generalized estimating equation 
models with separate between-subjects and within-subjects 
effects for the ARV predictor52,53 with the latter optionally 
parameterized to represent the average within-participant 
change in adherence over time since baseline. Changes since 
baseline in adherence will enable us to investigate whether 
adherence changed as a result of joining the study. Maximum 
likelihood estimation or multiple imputation will be used to 
address the missing data in inferential analyses under the 
missing at random assumption.54 Finally, we will conduct 
additional exploratory analyses as necessary.
Ethics approval and consent to 
participate
We received approval from the UCSF Institutional Review 
Board (IRB) to conduct this study and written consent from 
all participants.
Discussion
We have established a protocol, which we describe here for 
remotely conducting a study to assess the acceptability and 
feasibility of novel ARV medication adherence measurement 
approaches. While analyses evaluating the outcomes of the 
study are currently under way, the protocol established for 
this study was implemented successfully and offers guidance 
for others seeking to conduct research using similar method-
ologies. The advantages of tracking medication adherence 
both remotely and by these novel methods may translate 
to other HIV- and non-HIV-related studies; however, the 
implementation of the protocol to date has led to various 
lessons learned.
contact information
Because all activities were conducted remotely with no face-
to-face contact with participants, it was critical to collect 
and maintain multiple sources of contact information from 
enrollees. Relying on mobile telephone numbers only is 
insufficient in the not infrequent occurrence of lost or stolen 
telephones. Similarly, relying on email contact was often 
inadequate, as some individuals did not monitor their email 
accounts with regularity. Rather, a combination of text mes-
saging, emailing, and telephone calls was often needed to 
minimize the study attrition and loss to follow-up. Addition-
ally, we collected social media contact information.
remote payment
The use of reloadable debit cards allowed for remote and 
timely disbursement of payment for participation in study 
activities. We, therefore, established tips for the optimal use 
of the cards. When mailing out ClinCards, we recommend 
that study staff consider waiting until the participant has 
confirmed the receipt of the card in the mail before register-
ing the card to the individual and adding funds to the card. 
This avoids fraud resulting from others intercepting the card 
and allows the study to reuse the card should the envelope 
be returned in the mail. We also learned that it was wise to 
include a short information sheet with the mailed ClinCard, 
emphasizing that participants should treat the card like cash 
and to contact the study immediately if the card is lost or 
stolen, with the intent that this would preempt participant 
questions and assist with managing lost cards. We have cre-
ated such an information sheet for our future research: http://
rxpix.ucsf.edu/clincard-quick-info.
Home collection of hair samples
The use of home hair collection for medication adherence 
estimation offers great promise, but has never been attempted 
on the scale implemented in this study. The benefit of this 
method is that hair samples do not require a cold chain or 
biohazard precautions for storage or shipment. They provide 
a mean measure of drug uptake and exposure over weeks to 
months. However, they require a specialty laboratory, such 
as HAL for analysis and reporting. We noted a few important 
steps to help improve efficiency in data collection and data 
accuracy above and beyond our approach. We recommend 
including the participant’s unique identification number on 
the return envelope as well as the included sealable storage 
plastic bag. This facilitates the identification and documenta-
tion of the hair sample even if the participant fails to place 
it inside the storage bag provided. Additionally, a great deal 
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of staff effort went into following up with participants about 
late or missing hair samples. We later realized that it assisted 
some participants to be notified by text or email on the day 
that we mailed out the hair kits so they knew to expect it in 
the mail. Another method that may work is to frequently 
remind participants of their study schedule dates at specific 
time points (eg, monthly).
text messaging of photographs
The photographed documentation of refill dates from medi-
cation vials was likewise an innovative aspect of the study. 
This approach is simple and cost-effective, and provides an 
objective measure of medication adherence. The limitation 
of this approach is that some participants reported that their 
prescription label was on a medication box, which they had 
thrown away; therefore, we recommend instructing partici-
pants in this scenario to take a picture of the refill date as 
soon as they pick up the refill, rather than waiting until their 
monthly text date. Another challenge of the study protocol 
was that we were unable to document how many participants 
may have switched to receive their refills in an automated 
manner. This would have made them ineligible to originally 
enroll in the study as part of our exclusion criteria.
Similarly, photographed documentation of pill counts to 
elicit adherence is a novel method of estimating adherence. 
It too is simple and cost-effective, and provides an objective 
measure of medication adherence. However, in certain cases, 
it was difficult to track pills a participant may have taken 
that came from places other than their medication bottle (eg, 
borrowed pills from a partner or friend, pills taken during 
a hospital stay). We, therefore, recommend the inclusion of 
survey items to evaluate the occurrence and frequency of 
these deviations from the standard practice of taking pills 
from a designated prescription bottle. Finally, even though 
we inquired about stock medications, many participants did 
not know how many pills they had in addition to the ones they 
were using from their most recent medication bottle or had so 
many that they were unable to report an accurate count. Even 
though it may be time consuming, spending more time with 
each participant after enrollment and at the end of the study 
to establish an accurate number of stock medications will be 
very helpful to understanding pill count discrepancies.
Other limitations of this study include the potential lack 
of generalizability due to voluntary response bias, in that 
participants were self-selected volunteers for this research. 
Additionally, information related to demographics and other 
medical data were self-reported and, therefore, subject to 
recall bias.
In summary, this is the first study to examine the 3 novel 
methods to estimate ARV medication adherence among 
PLWH. Upon completion of data collection, we will analyze 
qualitative and quantitative data to examine the feasibility 
and acceptability of the remotely conducted research and the 
various methods to estimate ARV adherence, as well as the 
correlation of these estimations with each other. The expected 
outcome of this study is that these 3 novel methods will be 
feasible and acceptable, will have high levels of correlation 
with each other, and will contribute to the future adherence 
research. Since hair collection does not require a cold chain 
or biohazard precautions for storage or shipment, and estima-
tion of adherence based on text-messaged photographs of pill 
counts and refill dates is objective and cost-effective, these 
methods may be the important steps to expanding objective 
adherence monitoring tools in the context of HIV treatment 
and prevention studies worldwide.
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